OSHA Issues Workplace Guidance on Opioid Overdose Rescue as Part of National Recovery Push

The Occupational Safety and Health Administration on September 24, 2026, published a new fact sheet advising employers on how to prepare for and respond to opioid overdoses in the workplace, marking the first time the federal job-safety agency has issued dedicated guidance on the topic. The document arrives as part of the Trump administration's broader Great American Recovery Initiative and encourages businesses to stock naloxone or nalmefene, train employees to recognize overdose symptoms, and treat reversal kits with the same visibility as standard first aid supplies.

What the fact sheet recommends

OSHA's guidance, titled "Opioid Overdose Rescue with Reversal Medications," outlines a series of voluntary preparedness strategies. Employers are urged to keep FDA-approved overdose reversal medications on hand and store them in highly visible, easily accessible locations. The agency also recommends educating workers on how to spot the signs of an overdose—slow or stopped breathing, blue lips or skin, pinpoint pupils, and unresponsiveness—and training designated staff to administer the medication, position the individual safely, and provide care until emergency responders arrive.

The guidance explicitly states that it does not create any new OSHA-specific requirements under existing standards such as the agency's Medical Services and First Aid regulation or its recordkeeping rules. Employers remain free to decide whether to adopt the recommended measures, though the fact sheet notes that companies in states with their own OSHA-approved plans should check whether state law imposes additional obligations.

Context: drug use in the workforce

The release follows a July 2026 report from Quest Diagnostics finding that nearly one in five U.S. workers tested positive for drug use through hair analysis in 2025. The screening covered marijuana, cocaine, opiates, amphetamines, and methamphetamine. Among those tested, opiate use was highest among healthcare workers, a population that also faces elevated occupational stress and access to prescription medications.

White House Drug Czar Sara Carter tied the new guidance to the administration's emphasis on expanding access to life-saving tools. "Because fentanyl has infiltrated the illicit drug landscape and acts as a chemical weapon against our people, it is critically important that the American workforce is familiar with drug overdose recognition and reversal," Carter said in a statement. "I am grateful to the Department of Labor for informing employers and workers about life-saving overdose reversal treatments like naloxone."

Legal and workplace-policy implications

Employment-law attorneys at Littler Mendelson noted that while the guidance is advisory, employers who choose to stock naloxone should consider drafting a clear policy that addresses employees' right to refuse administration of the drug. They also cautioned that existing emergency response plans should be reviewed to ensure they adequately cover overdose scenarios, particularly in industries with higher rates of substance use or physical injury.

The guidance also intersects with existing employment law around addiction. The U.S. Equal Employment Opportunity Commission has pursued disability-discrimination cases related to substance use treatment, including a recent $80,000 settlement with a software company that allegedly fired an employee after he took leave for inpatient treatment for opiate addiction. The worker was participating in doctor-supervised medication-assisted treatment, and the EEOC said the termination violated the Americans with Disabilities Act because the employee was regarded as disabled.

A growing patchwork of workplace rules

OSHA's federal fact sheet adds to an uneven landscape of workplace overdose policies. A March 2026 bipartisan bill introduced in Congress would have required larger employers to maintain naloxone supplies, though that legislation has not advanced. Meanwhile, New York State proposed workplace opioid antagonist regulations in September 2026 that would go further than the federal guidance by imposing specific requirements on employers. Several cities and counties have also enacted their own ordinances mandating naloxone in public buildings and certain private workplaces.

The federal guidance does not resolve the broader question of whether naloxone should be treated as a mandatory workplace safety item like fire extinguishers or automated external defibrillators. For now, it represents a signaling effort from the administration—encouraging private-sector participation in overdose response without imposing binding rules.

What it means for workers seeking help

For employees struggling with opioid use, the guidance arrives alongside a policy environment that remains legally complex. While the Americans with Disabilities Act protects individuals who are in recovery and participating in treatment, active illegal drug use is not covered, and employers retain broad discretion to enforce drug-free workplace policies. Workers seeking medication-assisted treatment for opioid use disorder can find providers nationwide, but access varies significantly by insurance status, geography, and employer leave policies.

The OSHA fact sheet is available through the Department of Labor's website as part of a series of resources tied to the Great American Recovery Initiative, which has included federal grants for faith-based prevention, 988 crisis-line expansion, and block-grant funding for state treatment programs in recent weeks.